Foundation University Islamabad

fui.edu.pk

Total trials

218

Active

111

Phase 3

0

Total enrollment

10,076

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 8 of 8 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Topical 30% metformin cream2
Kligman's Regimen1
Study for the correlation of SNPs with efficacy and toxicity of Leflunomide in RA patients1
Pharmacological therapy1
topical 3% tranexamic acid solution1
Tacrolimus1
Crisaborole 2% Top Oint1
Botox injection into extraocular muscles1

Next readouts

  • 2025-01-01
  • 2026-06-30
  • 2026-11-01
  • 2026-12-01
  • 2026-12-01
  • 2030-08-30

Top conditions

  • Low Back Pain16
  • Balance12
  • Neck Pain11
  • Stroke6
  • Knee Osteoarthritis6
  • Adhesive Capsulitis6
  • Cervicogenic Headache5
  • Postural Balance5

Frequently asked questions about Foundation University Islamabad

How many clinical trials does Foundation University Islamabad have on ClinicalTrials.gov?
Foundation University Islamabad is listed as the lead sponsor on 218 clinical trials in ClinicalTrials.gov, 111 of which are currently active (recruiting, enrolling, or ongoing).
How many of Foundation University Islamabad's trials are in Phase 3?
0 of Foundation University Islamabad's trials are in Phase 3, spread across 8 active drug programs.
What therapeutic areas does Foundation University Islamabad focus on?
Foundation University Islamabad's most-studied conditions on ClinicalTrials.gov are Low Back Pain, Balance, Neck Pain, Stroke, Knee Osteoarthritis.
When are Foundation University Islamabad's next clinical trial readouts?
Foundation University Islamabad has 6 upcoming primary-completion readouts tracked here; the soonest is “Additive Effects of Alternative Nostril Breathing with Pharmacological Management on Dyspnea and Control Pause in Patients with Bronchial Asthma”, expected around 2025-01-01.